Results | Interim results were reported in 613 of 1267 screened publications. Of these, 72% (n = 442) reported on trials stopped early (for benefit, n = 105; harm, n = 67; futility, n = 224; or other problems, n = 46). The remaining 171 ongoing trials (mostly in oncology, surgery, or cardiology) reported interim efficacy or safety results ( Table 1) . Forty percent (n = 68) of the publications stated that the interim analysis was protocol specified but half (n = 86) provided no reason.
Final results were published for 61% (n = 98) of the 160 trials for which sufficient time elapsed for publication (ie, >1 year beyond trial registry-specified study completion date). Among the 73 matched pairs reporting the same efficacy or safety outcome, interim analyses had fewer participants (median, 205 vs 295 participants) and shorter follow-up (median, 48 vs 104 weeks) than final analyses (Table 2) . Interim and final publications had similar prominence, and most (79%; n = 58) abstract conclusions did not change: 32 consistently concluded the intervention was not different from the comparator and 26 consistently concluded the intervention was beneficial. Twenty-one percent (n = 15) Editorial page 350 changed: 4 from not different to beneficial, 3 from not different to harmful (or possibly harmful), 6 from beneficial to not different, 1 from beneficial to harmful, and 1 from inconclusive to noninferior (see examples in Table 2 ). The change from beneficial to harmful occurred because the harm of high-dose imatinib, which reduced event-free survival vs the standard dose, emerged in the final publication.
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Discussion | Many interim publications reported analyses without mention of prespecification or any justification. Frequent nonpublication of final results means true treatment effects often remain unknown. Interim and final publications had similar journal and media prominence, and most reached similar conclusions. However, in 21%, clinicians could have been misled about whether an intervention was beneficial, Beneficial → harmful First randomized phase 3 trial in patients with pretreated chronic-phase chronic myeloid leukemia demonstrating improvements in major cytogenetic response to complete cytogenetic response and major molecular response rates with high-dose imatinib therapy (Haematologica).
Standard-dose imatinib remains the standard of care for pretreated patients with chronic-phase chronic myeloid leukemia (high-dose imatinib reduced event-free survival) (Haematologica; NCT00327262).
Inconclusive → noninferior The noninferiority criterion was not met and overall survival results were inconclusive (Lancet Oncology).
Bevacizumab plus capecitabine for HER2-negative locally recurrent or metastatic breast cancer offering good tolerability without compromising overall survival vs bevacizumab plus paclitaxel (Lancet Oncology; NCT00600340).
Abbreviation: IQR, interquartile range. a Percentages may not add to total because of rounding.
b P values for paired differences (McNemar test for dichotomous variables and signed rank test for continuous variables). c Altmetric attention scores were available for 37 interim and 48 final publications. d Not different indicates that the intervention is not statistically significantly different than placebo or meets noninferiority criterion for active control. Beneficial indicates that the intervention is statistically significantly better than placebo or active control. Harmful indicates that the intervention is statistically significantly worse than placebo or active control (1 of the 3 pairs of publications that changed from not different to harmful was possibly harmful because it had a P = .05, but the abstract conclusion raised concern about a possible increase in deaths due to the intervention). harmful, or ineffective. Limitations include underestimation of interim publications (full text not searched), the final publication rate (missed publications or misclassified trials eligible for publication), and the extent of interim to final changes (only 1 key outcome analyzed). Interim publication should be limited to protocolprespecified analyses performed when enough outcomes occurred for statistical stability and to scenarios least likely to undermine trial integrity (eg, crossovers cannot happen in a trial testing 2 surgical techniques after all patients have had surgery). Routinely including the word "interim" in the title and justifying the reason in the publication would help alert readers to inherent uncertainties. Journals, authors, and funders should commit to making final results accessible by linking interim publications to final reports whenever available.
